Loading data for BBLGW — first visit, this takes a few seconds.
Bone Biologics Corporation (BBLGW)
NasdaqCM: BBLGW
· Real-Time Price · USD
8.24
+3.70 (81.50%)
At close: Sep 10, 2026, 7:24 PM
The price, the headline numbers and the latest news, in one place.
Bone Biologics Corporation (BBLGW) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.89M |
| 0.50 | |
| -0.14 | |
| n/a | |
| n/a | |
| P/B (ttm) | 2.09 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 0 |
| Volume | 14 |
| Avg. Volume (20D) | 422 |
| Open | 9.97 |
| Previous Close | 4.54 |
| Day's Range | 8.24 - 8.95 |
| 52-Week Range | 3.50 - 35.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BBLGW
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, a...
IPO Date Oct 13, 2021
Employees 2
Stock Exchange NasdaqCM
Ticker Symbol BBLGW
Website https://www.bonebiologics.com
Financial Performance
In 2025, Bone Biologics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -3.11M, a decrease of -24.4%.
Financial StatementsEarnings Surprise
Bone Biologics has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
1 year ago · Associated Press Finance
BC-Most Active Stockstd class="col-issue">Next Technology Holding Inc.